The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Ischemic Stroke Drugs Market Research Report 2025
Synopsis
Acute Ischemic Stroke (CIS), also known as Cerebral Infarction (CI), is due to the occlusion of the Cerebral artery caused by the Infarction of brain tissue, accompanied by damage to neurons, astrocytes, oligodendrocytes, is the modern society leading to death and disability of the most important central nervous system vascular events.
The global Acute Ischemic Stroke Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Acute Ischemic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Acute Ischemic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Acute Ischemic Stroke Drugs in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Acute Ischemic Stroke Drugs include Sanofi, Biogen, Bayer, Pfizer, Roche, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb and Johnson＆Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Acute Ischemic Stroke Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Ischemic Stroke Drugs.
Report Scope
The Acute Ischemic Stroke Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Ischemic Stroke Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Ischemic Stroke Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Biogen
Bayer
Pfizer
Roche
Boehringer Ingelheim
Daiichi Sankyo
Bristol-Myers Squibb
Johnson＆Johnson
AstraZeneca
ZZ Biotech
NoNO Inc
Athersys
SanBio
Segment by Type
Tablet
Capsule
Other
Segment by Application
Hospitals
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Ischemic Stroke Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Acute Ischemic Stroke (CIS), also known as Cerebral Infarction (CI), is due to the occlusion of the Cerebral artery caused by the Infarction of brain tissue, accompanied by damage to neurons, astrocytes, oligodendrocytes, is the modern society leading to death and disability of the most important central nervous system vascular events.
The global Acute Ischemic Stroke Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Acute Ischemic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Acute Ischemic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Acute Ischemic Stroke Drugs in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Acute Ischemic Stroke Drugs include Sanofi, Biogen, Bayer, Pfizer, Roche, Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb and Johnson＆Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Acute Ischemic Stroke Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Ischemic Stroke Drugs.
Report Scope
The Acute Ischemic Stroke Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Ischemic Stroke Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Ischemic Stroke Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Biogen
Bayer
Pfizer
Roche
Boehringer Ingelheim
Daiichi Sankyo
Bristol-Myers Squibb
Johnson＆Johnson
AstraZeneca
ZZ Biotech
NoNO Inc
Athersys
SanBio
Segment by Type
Tablet
Capsule
Other
Segment by Application
Hospitals
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Ischemic Stroke Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Ischemic Stroke Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablet
1.2.3 Capsule
1.2.4 Other
1.3 Market by Application
1.3.1 Global Acute Ischemic Stroke Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Diagnostic Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Ischemic Stroke Drugs Market Perspective (2019-2030)
2.2 Acute Ischemic Stroke Drugs Growth Trends by Region
2.2.1 Global Acute Ischemic Stroke Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acute Ischemic Stroke Drugs Historic Market Size by Region (2019-2024)
2.2.3 Acute Ischemic Stroke Drugs Forecasted Market Size by Region (2025-2030)
2.3 Acute Ischemic Stroke Drugs Market Dynamics
2.3.1 Acute Ischemic Stroke Drugs Industry Trends
2.3.2 Acute Ischemic Stroke Drugs Market Drivers
2.3.3 Acute Ischemic Stroke Drugs Market Challenges
2.3.4 Acute Ischemic Stroke Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Ischemic Stroke Drugs Players by Revenue
3.1.1 Global Top Acute Ischemic Stroke Drugs Players by Revenue (2019-2024)
3.1.2 Global Acute Ischemic Stroke Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Acute Ischemic Stroke Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Ischemic Stroke Drugs Revenue
3.4 Global Acute Ischemic Stroke Drugs Market Concentration Ratio
3.4.1 Global Acute Ischemic Stroke Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Ischemic Stroke Drugs Revenue in 2023
3.5 Acute Ischemic Stroke Drugs Key Players Head office and Area Served
3.6 Key Players Acute Ischemic Stroke Drugs Product Solution and Service
3.7 Date of Enter into Acute Ischemic Stroke Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Ischemic Stroke Drugs Breakdown Data by Type
4.1 Global Acute Ischemic Stroke Drugs Historic Market Size by Type (2019-2024)
4.2 Global Acute Ischemic Stroke Drugs Forecasted Market Size by Type (2025-2030)
5 Acute Ischemic Stroke Drugs Breakdown Data by Application
5.1 Global Acute Ischemic Stroke Drugs Historic Market Size by Application (2019-2024)
5.2 Global Acute Ischemic Stroke Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Acute Ischemic Stroke Drugs Market Size (2019-2030)
6.2 North America Acute Ischemic Stroke Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acute Ischemic Stroke Drugs Market Size by Country (2019-2024)
6.4 North America Acute Ischemic Stroke Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Ischemic Stroke Drugs Market Size (2019-2030)
7.2 Europe Acute Ischemic Stroke Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acute Ischemic Stroke Drugs Market Size by Country (2019-2024)
7.4 Europe Acute Ischemic Stroke Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Ischemic Stroke Drugs Market Size (2019-2030)
8.2 Asia-Pacific Acute Ischemic Stroke Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acute Ischemic Stroke Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Acute Ischemic Stroke Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Ischemic Stroke Drugs Market Size (2019-2030)
9.2 Latin America Acute Ischemic Stroke Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acute Ischemic Stroke Drugs Market Size by Country (2019-2024)
9.4 Latin America Acute Ischemic Stroke Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Ischemic Stroke Drugs Market Size (2019-2030)
10.2 Middle East & Africa Acute Ischemic Stroke Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acute Ischemic Stroke Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Acute Ischemic Stroke Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Acute Ischemic Stroke Drugs Introduction
11.1.4 Sanofi Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Biogen
11.2.1 Biogen Company Detail
11.2.2 Biogen Business Overview
11.2.3 Biogen Acute Ischemic Stroke Drugs Introduction
11.2.4 Biogen Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.2.5 Biogen Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Acute Ischemic Stroke Drugs Introduction
11.3.4 Bayer Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Acute Ischemic Stroke Drugs Introduction
11.4.4 Pfizer Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Acute Ischemic Stroke Drugs Introduction
11.5.4 Roche Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Acute Ischemic Stroke Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Detail
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Acute Ischemic Stroke Drugs Introduction
11.7.4 Daiichi Sankyo Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.7.5 Daiichi Sankyo Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Acute Ischemic Stroke Drugs Introduction
11.8.4 Bristol-Myers Squibb Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Johnson＆Johnson
11.9.1 Johnson＆Johnson Company Detail
11.9.2 Johnson＆Johnson Business Overview
11.9.3 Johnson＆Johnson Acute Ischemic Stroke Drugs Introduction
11.9.4 Johnson＆Johnson Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.9.5 Johnson＆Johnson Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Detail
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Acute Ischemic Stroke Drugs Introduction
11.10.4 AstraZeneca Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.10.5 AstraZeneca Recent Development
11.11 ZZ Biotech
11.11.1 ZZ Biotech Company Detail
11.11.2 ZZ Biotech Business Overview
11.11.3 ZZ Biotech Acute Ischemic Stroke Drugs Introduction
11.11.4 ZZ Biotech Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.11.5 ZZ Biotech Recent Development
11.12 NoNO Inc
11.12.1 NoNO Inc Company Detail
11.12.2 NoNO Inc Business Overview
11.12.3 NoNO Inc Acute Ischemic Stroke Drugs Introduction
11.12.4 NoNO Inc Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.12.5 NoNO Inc Recent Development
11.13 Athersys
11.13.1 Athersys Company Detail
11.13.2 Athersys Business Overview
11.13.3 Athersys Acute Ischemic Stroke Drugs Introduction
11.13.4 Athersys Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.13.5 Athersys Recent Development
11.14 SanBio
11.14.1 SanBio Company Detail
11.14.2 SanBio Business Overview
11.14.3 SanBio Acute Ischemic Stroke Drugs Introduction
11.14.4 SanBio Revenue in Acute Ischemic Stroke Drugs Business (2019-2024)
11.14.5 SanBio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
